View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
February 17, 2020

Merck’s Ebola vaccine Ervebo available in four African countries

Merck (MSD) has received approval from four African countries for its Ervebo vaccine to prevent disease caused by Zaire ebolavirus.

Merck (MSD) has received approval from four African countries for its Ervebo vaccine to prevent disease caused by Zaire ebolavirus.

Currently, the Democratic Republic of the Congo (DRC), Burundi, Ghana and Zambia have licensed the Ebola Zaire Vaccine, Live, with additional countries in Africa expected to register the vaccine in the coming weeks.

The licensing allows Merck to stockpile and distribute the vaccine to African countries at risk of Ebola virus disease outbreaks.

An Ebola outbreak is ongoing in the DRC, with more than 290,000 people vaccinated in line with compassionate use protocols.

After Merck makes licensed doses available, the vaccinations in DRC will not require these protocols.

Ervebo’s licensing and distribution was facilitated by the prequalification status awarded by the World Health Organization (WHO) last November.

To make registrations possible, WHO worked with the African Vaccines Regulatory Forum (AVAREF), African governments, the European Medicines Agency (EMA) and Merck.

WHO Africa regional director Dr Matshidiso Moeti said: “The rapid approval of the Ebola vaccine by countries in the Africa Region helps ensure this critical prevention tool will be available when and where it is needed most.”

Ervebo secured the European Commission conditional marketing authorisation in November, while the US Food and Drug Administration approved the vaccine in December.

In the US, the vaccine is indicated for individuals aged 18 years and older but does not offer protection from other species of Ebolavirus or Marburgvirus.

Merck chairman and CEO Kenneth Frazier said: “While we are far from finished in the Ebola fight, this milestone shows what can be done when we work together to address the most challenging diseases that threaten people and communities.”

The company is working towards the production of licensed doses and expects them to be available in the third quarter of this year.

Furthermore, Merck is working with the US government, WHO, UNICEF and Gavi Vaccine Alliance on future, licensed doses use in public health preparedness and Zaire ebolavirus disease response efforts.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Pharmaceutical Technology